Skip to main content
Top
Published in: Journal of Neuro-Oncology 1/2008

01-10-2008 | clinical-patient studies

Medulloblastoma in children: a 32-year experience from a single institution

Authors: Canan Akyüz, Ali Varan, Serhan Küpeli, Nejat Akalan, Figen Söylemezoglu, Faruk Zorlu, Tezer Kutluk, Münevver Büyükpamukçu

Published in: Journal of Neuro-Oncology | Issue 1/2008

Login to get access

Abstract

We retrospectively evaluated 203 patients newly diagnosed with medulloblastoma between 1975 and 2006. All patients underwent surgical resection and after surgery were treated with a combination of radiotherapy and chemotherapy. CCNU-based protocols were used in the early years, with CDDP+VP16 being used more recently. Radiotherapy was used in patients older than three years of age according to the protocols. One hundred fifteen patients had total surgical resection, 78 had subtotal resection, and 4 patients had only a biopsy. Every patient received chemotherapy: 124 with the CCNU-based protocol, 75 with CDDP+VP16, and 4 with other protocols. Overall (OS) and event free-survival (EFS) rates were 43.1 and 41.9% in the whole group, with a median follow-up time of 8 years. OS rates for patients with and without spinal seeding were 30 and 63.1% (P = 0.0002). OS rates for males and females were 36.2 and 54.7% (P = 0.03). OS rates for patients receiving the CCNU and CDDP+VP16 protocols were 41.1 and 45%.
Literature
1.
go back to reference Blaney SM, Kun LE, Hunter J et al (2006) Tumors of the central nervous system. In: Pizzo PA, Poplack DG (eds) Principles and Practice of Pediatric Oncology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 786–864 Blaney SM, Kun LE, Hunter J et al (2006) Tumors of the central nervous system. In: Pizzo PA, Poplack DG (eds) Principles and Practice of Pediatric Oncology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 786–864
2.
go back to reference Eberhart CG, Chaudhry A, Daniel RW (2005) Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer 5:19CrossRefPubMed Eberhart CG, Chaudhry A, Daniel RW (2005) Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer 5:19CrossRefPubMed
3.
go back to reference Zeltzer PM, Boyett JM, Finlay JL et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17:832–845PubMed Zeltzer PM, Boyett JM, Finlay JL et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17:832–845PubMed
4.
go back to reference Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumors of the nervous system: World Health Organization classification of tumors. IARC Press, Lyon Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumors of the nervous system: World Health Organization classification of tumors. IARC Press, Lyon
5.
go back to reference Polkinghorn WR, Tarbell NJ (2007) Medulloblastoma: tumorigenesis, current clinical paradigm and efforts to improve risk stratification. Nat Clin Pract Oncol 4:295–304CrossRefPubMed Polkinghorn WR, Tarbell NJ (2007) Medulloblastoma: tumorigenesis, current clinical paradigm and efforts to improve risk stratification. Nat Clin Pract Oncol 4:295–304CrossRefPubMed
6.
go back to reference Eberhart CG, Kepner JL, Goldthwaite PT et al (2002) Histopathologic grading of medulloblastomas. A pediatric oncology group study. Cancer 94:552–560 Eberhart CG, Kepner JL, Goldthwaite PT et al (2002) Histopathologic grading of medulloblastomas. A pediatric oncology group study. Cancer 94:552–560
7.
go back to reference Bailey CC, Gnekow A, Wellek S et al (1995) Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 25:166–178 Bailey CC, Gnekow A, Wellek S et al (1995) Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 25:166–178
8.
go back to reference Jenkin D, Shabanah MA, Shail EA et al (2000) Prognostic factors for medulloblastoma. Int J Radiat Oncol Biol Phys 47:573–584CrossRefPubMed Jenkin D, Shabanah MA, Shail EA et al (2000) Prognostic factors for medulloblastoma. Int J Radiat Oncol Biol Phys 47:573–584CrossRefPubMed
9.
go back to reference Weil MD, Lamborn K, Edwards MS et al (1998) Influence of a child’s sex on medulloblastoma outcome. JAMA 279:1474–1476CrossRefPubMed Weil MD, Lamborn K, Edwards MS et al (1998) Influence of a child’s sex on medulloblastoma outcome. JAMA 279:1474–1476CrossRefPubMed
10.
go back to reference Danjoux CE, Jenkin RDT, McLaughlin J et al (1996) Childhood medulloblastoma in Ontario, 1977–1987: population based results. Med Pediatr Oncol 26:1–9CrossRefPubMed Danjoux CE, Jenkin RDT, McLaughlin J et al (1996) Childhood medulloblastoma in Ontario, 1977–1987: population based results. Med Pediatr Oncol 26:1–9CrossRefPubMed
11.
go back to reference Gilbertson RJ, Jaros E, Perry RH et al (1997) Mitotic percentage index: a new prognostic factor for childhood medulloblastoma. Eur J Cancer 33:609–615CrossRefPubMed Gilbertson RJ, Jaros E, Perry RH et al (1997) Mitotic percentage index: a new prognostic factor for childhood medulloblastoma. Eur J Cancer 33:609–615CrossRefPubMed
12.
go back to reference Urberuaga A, Navajas A, Burgos J, Pijoan JI (2006) A review of clinical and histological features of Spanish paediatric medulloblastomas during the last 21 years. Childs Nerv Syst 22:466–474CrossRefPubMed Urberuaga A, Navajas A, Burgos J, Pijoan JI (2006) A review of clinical and histological features of Spanish paediatric medulloblastomas during the last 21 years. Childs Nerv Syst 22:466–474CrossRefPubMed
13.
go back to reference Varan A, Akalan N, Söylemezoğlu F et al (2006) Central nervous system tumors in patients under three years of age: treatment results of a single institute. Pediatr Neurosurg 42:89–94CrossRefPubMed Varan A, Akalan N, Söylemezoğlu F et al (2006) Central nervous system tumors in patients under three years of age: treatment results of a single institute. Pediatr Neurosurg 42:89–94CrossRefPubMed
14.
go back to reference Packer RJ, Sutton LN, Elterman R et al (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU and vincristine chemotherapy. J Neurosurg 81:690–698CrossRefPubMed Packer RJ, Sutton LN, Elterman R et al (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU and vincristine chemotherapy. J Neurosurg 81:690–698CrossRefPubMed
15.
go back to reference Packer RJ, Goldwein J, Nicholson HS et al (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol 17:2127–2136PubMed Packer RJ, Goldwein J, Nicholson HS et al (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol 17:2127–2136PubMed
16.
go back to reference Padovani L, Sunyach MP, Perol D et al (2007) Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 68:433–440CrossRefPubMed Padovani L, Sunyach MP, Perol D et al (2007) Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 68:433–440CrossRefPubMed
17.
go back to reference Delcharco JO, Bolek TW, McCollough WM et al (1998) Medulloblastoma: time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 42:147–154 Delcharco JO, Bolek TW, McCollough WM et al (1998) Medulloblastoma: time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 42:147–154
18.
go back to reference Prados MD, Edwards MSB, Chang SM et al (1999) Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a phase II study. Int J Radiat Oncol Biol Phys 43:279–285CrossRefPubMed Prados MD, Edwards MSB, Chang SM et al (1999) Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a phase II study. Int J Radiat Oncol Biol Phys 43:279–285CrossRefPubMed
19.
go back to reference Matsutani M (2004) Chemoradiotherapy for brain tumors: current status and perspectives. Int J Clin Oncol 9:471–474CrossRefPubMed Matsutani M (2004) Chemoradiotherapy for brain tumors: current status and perspectives. Int J Clin Oncol 9:471–474CrossRefPubMed
20.
go back to reference Kortmann RD, Kühl J, Timmermann B et al (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ‘91. Int J Radiat Oncol Biol Phys 46:269–279CrossRefPubMed Kortmann RD, Kühl J, Timmermann B et al (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ‘91. Int J Radiat Oncol Biol Phys 46:269–279CrossRefPubMed
Metadata
Title
Medulloblastoma in children: a 32-year experience from a single institution
Authors
Canan Akyüz
Ali Varan
Serhan Küpeli
Nejat Akalan
Figen Söylemezoglu
Faruk Zorlu
Tezer Kutluk
Münevver Büyükpamukçu
Publication date
01-10-2008
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2008
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-008-9638-x

Other articles of this Issue 1/2008

Journal of Neuro-Oncology 1/2008 Go to the issue